10 analysts have expressed a variety of opinions on Avidity Biosciences (NASDAQ:RNA) over the past quarter, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 4 | 6 | 0 | 0 | 0 |
Last 30D | 1 | 0 | 0 | 0 | 0 |
1M Ago | 1 | 0 | 0 | 0 | 0 |
2M Ago | 0 | 5 | 0 | 0 | 0 |
3M Ago | 2 | 1 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Avidity Biosciences, presenting an average target of $71.5, a high estimate of $96.00, and a low estimate of $53.00. This upward trend is apparent, with the current average reflecting a 4.38% increase from the previous average price target of $68.50.
Login or create a forever free account to read this news
Sign up/Log in